Latest Clinical Trials
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) Merck Sharp & Dohme LLC NA
COMPLETED
(Sep 1, 2026)
PHASE2 Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE2 A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE1 A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3 A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) Merck Sharp & Dohme LLC NA
COMPLETED
(Sep 1, 2026)
PHASE2 Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE2 Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE2 A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE2 A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3 A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE1 A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE2 A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3 A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE2 A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3 A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01) Merck Sharp & Dohme LLC NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) Merck Sharp & Dohme LLC NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055) Merck Sharp & Dohme LLC NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) Merck Sharp & Dohme LLC NA
COMPLETED
(Aug 1, 2026)
PHASE3 KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) Merck Sharp & Dohme LLC NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) Merck Sharp & Dohme LLC NA
TERMINATED
(Aug 1, 2026)
PHASE2 A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension Merck Sharp & Dohme LLC NA
COMPLETED
(Aug 1, 2026)
PHASE3 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014). Merck Sharp & Dohme LLC NA
TERMINATED
(Aug 1, 2026)
PHASE3 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) Merck Sharp & Dohme LLC NA
TERMINATED
(Aug 1, 2026)
PHASE3 A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036) Merck Sharp & Dohme LLC NA
RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids Merck Sharp & Dohme LLC NA
COMPLETED
(Aug 1, 2026)
PHASE3 Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001) Merck Sharp & Dohme LLC NA
COMPLETED
(Aug 1, 2026)
PHASE1 A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) Merck Sharp & Dohme LLC NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) Merck Sharp & Dohme LLC NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01) Merck Sharp & Dohme LLC NA
RECRUITING
(Aug 1, 2026)
PHASE2 Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) Merck Sharp & Dohme LLC NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) Merck Sharp & Dohme LLC NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) Merck Sharp & Dohme LLC NA
RECRUITING
(Aug 1, 2026)
PHASE3 A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) Merck Sharp & Dohme LLC NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) Merck Sharp & Dohme LLC NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005) Merck Sharp & Dohme LLC NA
COMPLETED
(Aug 1, 2026)
PHASE1 A Clinical Trial in Healthy Participants to Learn How Itraconazole Affects MK-2828 Levels and How MK-2828 Affects Midazolam Levels (MK-2828-007) Merck Sharp & Dohme LLC NA
COMPLETED
(Aug 1, 2026)
PHASE1 A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Participants (MK-4646) Merck Sharp & Dohme LLC NA
COMPLETED
(Aug 1, 2026)
PHASE1 A Clinical Trial of MK-4082 in Healthy Participants (MK-4082-005) Merck Sharp & Dohme LLC NA
RECRUITING
(Aug 1, 2026)
PHASE1 A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) Merck Sharp & Dohme LLC NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038) Merck Sharp & Dohme LLC NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) Merck Sharp & Dohme LLC NA
COMPLETED
(Jul 1, 2026)
PHASE3 Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866) Merck Sharp & Dohme LLC NA
COMPLETED
(Jul 1, 2026)
PHASE3 Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) Merck Sharp & Dohme LLC NA
COMPLETED
(Jul 1, 2026)
PHASE3 Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) Merck Sharp & Dohme LLC NA
COMPLETED
(Jul 1, 2026)
PHASE3 Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066) Merck Sharp & Dohme LLC NA
RECRUITING
(Jul 1, 2026)
PHASE2 Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127) Merck Sharp & Dohme LLC NA
RECRUITING
(Jul 1, 2026)
PHASE2 Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99) Merck Sharp & Dohme LLC NA
COMPLETED
(Jul 1, 2026)
PHASE2 Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) Merck Sharp & Dohme LLC NA
COMPLETED
(Jul 1, 2026)
PHASE3 A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) Merck Sharp & Dohme LLC NA
RECRUITING
(Jul 1, 2026)
PHASE3 A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019) Merck Sharp & Dohme LLC NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE1 Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) Merck Sharp & Dohme LLC NA
COMPLETED
(Jun 1, 2026)
PHASE3 Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) Merck Sharp & Dohme LLC NA
COMPLETED
(Jun 1, 2026)
PHASE3 Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007) Merck Sharp & Dohme LLC NA
COMPLETED
(Jun 1, 2026)
PHASE2 Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020) Merck Sharp & Dohme LLC NA
COMPLETED
(Jun 1, 2026)
PHASE3 A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017) Merck Sharp & Dohme LLC NA
COMPLETED
(Jun 1, 2026)
PHASE1 KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C) Merck Sharp & Dohme LLC NA
COMPLETED
(May 1, 2026)
PHASE2 Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Efficacy, Immunogenicity, and Safety Study of V503 (9-valent Human Papillomavirus [9vHPV] Vaccine) in Japanese Males (V503-064) Merck Sharp & Dohme LLC NA
COMPLETED
(May 1, 2026)
PHASE3 A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018) Merck Sharp & Dohme LLC NA
COMPLETED
(May 1, 2026)
PHASE1 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) Merck Sharp & Dohme LLC NA
COMPLETED
(May 1, 2026)
PHASE3 A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002) Merck Sharp & Dohme LLC NA
COMPLETED
(May 1, 2026)
PHASE1, PHASE2 Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) Merck Sharp & Dohme LLC NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Elpipodect (MK-8189) Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003) Merck Sharp & Dohme LLC NA
COMPLETED
(Apr 1, 2026)
PHASE1 An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005) Merck Sharp & Dohme LLC NA
COMPLETED
(Apr 1, 2026)
PHASE2 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) Merck Sharp & Dohme LLC NA
COMPLETED
(Apr 1, 2026)
PHASE3 A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008) Merck Sharp & Dohme LLC NA
COMPLETED
(Apr 1, 2026)
PHASE2 Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024) Merck Sharp & Dohme LLC NA
TERMINATED
(Apr 1, 2026)
PHASE3 Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015) Merck Sharp & Dohme LLC NA
COMPLETED
(Apr 1, 2026)
PHASE3 Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study Merck Sharp & Dohme LLC NA
COMPLETED
(Apr 1, 2026)
PHASE3 Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005) Merck Sharp & Dohme LLC NA
COMPLETED
(Apr 1, 2026)
PHASE1 Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) Merck Sharp & Dohme LLC NA
COMPLETED
(Mar 1, 2026)
PHASE3 Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65). Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE3 A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001) Merck Sharp & Dohme LLC NA
COMPLETED
(Mar 1, 2026)
PHASE1 A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn) Merck Sharp & Dohme LLC NA
COMPLETED
(Mar 1, 2026)
PHASE3 A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008) Merck Sharp & Dohme LLC NA
COMPLETED
(Jan, 2019)
PHASE2 A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004) Merck Sharp & Dohme LLC NA
TERMINATED
(Dec, 2018)
PHASE1 A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014) Merck Sharp & Dohme LLC NA
COMPLETED
(Dec, 2018)
PHASE1 A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013) Merck Sharp & Dohme LLC NA
COMPLETED
(Dec, 2018)
PHASE1 
